| Document |
Document Title |
|
WO/2020/011243A1 |
Disclosed are compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders s...
|
|
WO/2020/009442A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2020/009441A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2019/206120A1 |
The present invention relates to a formamide compound, a preparation method therefor and an application thereof. The structure of the compound is shown in formula (I), and the definition of each variable in the formula is as provided in ...
|
|
WO/2019/166304A1 |
The invention relates to benzoyl amides of general formula (I) as herbicides. In formula (I), B, X1 and X2 represent N, O or S(O)n. R, Ra, Rb, Rc, Rd und Rx stand for groups such as hydrogen, halogen, (C1-C6) alkyl, halogen-(C1-C6) alkyl...
|
|
WO/2019/134707A1 |
Provided are a compound as presented in formula (I), a tautomer and enantiomer thereof, or a pharmaceutically acceptable salt, a cristal form, a hydrate or a solvate thereof. The compound of formula (I) can be effectively combined with S...
|
|
WO/2019/125185A1 |
The invention provides novel quinoline sulfonamide compounds of Formula I: (Formula (I)) and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, ...
|
|
WO/2019/104418A1 |
There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6' and X6'' are selected from H, haloge...
|
|
WO/2019/096884A1 |
The invention relates to benzoyl amides of general formula (I), as herbicides. In formula (I), B is N or CH, and X1 and X2 are O or S(O)n. R, Ra and Rb are groups such as hydrogen, halogen, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl, (C1-C6)-a...
|
|
WO/2019/065283A1 |
Provided are a novel pyridazinone compound or a salt thereof useful as an active ingredient of an herbicide and an herbicide and control method using the same. A pyridazinone compound represented by general formula (I) or a salt thereof....
|
|
WO/2019/037742A1 |
Disclosed in the present invention are an imidazolone androgen receptor antagonist, a preparation method therefor and use thereof. The imidazolone androgen receptor antagonist of the present invention has a structure represented by formu...
|
|
WO/2019/034469A1 |
Process for the preparation of a compound with at least one five-membered cyclic monothiocar- bonate group wherein a) a compound with at least one epoxy group is used as starting material b) the compound is reacted with phosgene or an al...
|
|
WO/2019/017814A9 |
The present invention relates to novel hepatitis B virus (HBV) inhibitors for use as chemotherapeutic agents for treating HBV. The compounds bind to HBV core-antigen and trigger the formation of aberrant virus capsids not carrying the vi...
|
|
WO/2019/025156A1 |
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crop cultivation and/or as plant growth regulators for influencing the growth o...
|
|
WO/2019/022002A1 |
A compound represented by formula (I) or a salt thereof. (In formula (I), Q1 represents an (un)substituted C6-10 aryl group; Q2 represents an (un)substituted C1-6 alkyl group, an (un)substituted C6-10 aryl group, or a five- to ten-member...
|
|
WO/2019/023553A1 |
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...
|
|
WO/2019/008119A1 |
The invention relates to a compound of the following formula (I), a method for producing same, the synthesis intermediates thereof, and uses thereof as a hypoxia imaging agent.
|
|
WO/2019/009759A1 |
The present invention relates to a novel combined medicinal preparation having a solid oral dosage form and comprising as one of three active ingredients elsulfavirine sodium, which could be used in medicine for treating viral infections...
|
|
WO/2018/204164A1 |
Disclosed are compounds of Formula (1), including all stereoisomers, N-oxides, and salts thereof (Formula (1)) wherein K, Z, R2, R3 and m are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxide...
|
|
WO/2018/178722A1 |
The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further pro...
|
|
WO/2018/091153A1 |
The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SER...
|
|
WO/2018/014829A1 |
The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossif...
|
|
WO/2018/003924A1 |
Provided is a novel pest control agent, especially a bactericide or a nematicide. An alkynylpyridine-substituted amide compound represented by formula (I) or a salt thereof; and a pest control agent which contains the compound or the sal...
|
|
WO/2017/216709A2 |
This invention provides for flow and batch synthesis processes for the production of Lamivudine and Emtricitabine, including flow and batch synthesis processes wherein at least of the synthesis steps are conducted in a solvent free envir...
|
|
WO/2017/210794A1 |
There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated wit...
|
|
WO/2017/162661A1 |
The present invention covers 1 /-/-benzo[c/e]isoquinoline-1,3(2/-/)-dione compounds of general formula (I) compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined according to claim 1 and methods of preparing sai...
|
|
WO/2017/144150A2 |
The present invention relates to a process to produce compounds of the formula (1) which are suitable for use in electronic devices, as well as to intermediate compounds of formula (lnt-1) and compounds of formula (1-1) and (1-2) obtaine...
|
|
WO/2017/146246A1 |
The purpose of the present invention is to provide a compound having excellent antibacterial activity against Mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria and/or non-tuberculous acid-fast bacteria. A compound rep...
|
|
WO/2017/137319A1 |
The present invention relates to compounds of the general formula (I), in which Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
|
WO/2017/139569A1 |
This invention relates to novel 4,4,5,5,7,7-hexamethyl-5,7-dihydro-4H-thieno[2,3-c]pyranyl compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and th...
|
|
WO/2017/137339A1 |
The present invention relates to compounds of the general formula (I), where to Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
|
WO/2016/173019A1 |
The present invention relates to a conjugated compound containing a phenoxathiin structure, a method for preparing same, and an organic electroluminescent diode device. The conjugated compound containing a phenoxathiin structure has a ch...
|
|
WO/2016/165007A1 |
This invention provides of compounds having structures of Formula A, uses of these compounds for treatment of various indications, including breast cancer, as well as methods of treatment involving these compounds.
|
|
WO/2016/127924A1 |
The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acce...
|
|
WO/2016/118774A1 |
The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfuncti...
|
|
WO/2016/097071A1 |
Described herein are compounds that are estrogen receptor modulators of Formula (I) and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with th...
|
|
WO/2016/078584A1 |
Provided is an emtricitabine purification method. The method comprises: separating out the emtricitabine in the form of emtricitabine benzoate from aqueous solution, and dissociating the benzoate to obtain high purity of the emtricitabin...
|
|
WO/2016/065264A1 |
Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/ NF-κΒ pathways....
|
|
WO/2016/054805A1 |
The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of eryt...
|
|
WO/2016/043558A1 |
The present invention relates to a compound, wherein the compound comprises at least one structural element A and at least one structural element B, wherein - structural element A is capable of releasing an acid upon exposure to electrom...
|
|
WO/2016/038583A1 |
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provid...
|
|
WO/2016/016118A1 |
Compounds of theformula (I), wherein X and Y are independently O, S or NR5, R1, R2 and R4 are independently hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy, R5 is halogen, cyano, C1-C6alkyl or C1- C6haloalky...
|
|
WO/2015/177110A1 |
The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl; Ar2 is a 5 or 6 membered heteroaryl group, containing 2...
|
|
WO/2015/174215A1 |
An actinic ray-sensitive or radiation-sensitive resin composition comprising a photoacid generator and resin (B), said resin composition comprising, as the photoacid generator, at least photoacid generator (A) represented by general form...
|
|
WO/2015/163435A1 |
Provided are compounds that exhibit an excellent autotaxin (ATX) inhibitory effect, etc. and are efficacious as a prophylactic or therapeutic agent for diseases in which ATX participates. Compounds represented by general formula (I) [whe...
|
|
WO/2015/144813A1 |
The present invention relates to N-acylimino compound of formula (I). The invention also relates to the use of the N-acylimino heterocyclic compounds of formula (I), their stereoisomers, their tautomers and their salts, for combating inv...
|
|
WO/2015/125824A1 |
Provided is a novel noxious organism control agent, particularly a bactericidal agent and a nematicidal agent. An alkynylpyridine-substituted amide compound represented by formula (I), an N-oxide of the compound, or a salt of the compoun...
|
|
WO/2015/103526A1 |
Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-t...
|
|
WO/2015/089220A1 |
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
|
|
WO/2015/089027A1 |
There is provided a hole transport material having Formula I, Formula Ia, or Formula II: In the formulae: A is an aromatic moiety including at least one triarylamino group; B' is an aromatic moiety; E is an end group which is H, D, alkyl...
|
